These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16939519)

  • 1. Geographic differences in event rates by model for end-stage liver disease score.
    Roberts JP; Dykstra DM; Goodrich NP; Rush SH; Merion RM; Port FK
    Am J Transplant; 2006 Oct; 6(10):2470-5. PubMed ID: 16939519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographic inequity in access to livers for transplantation.
    Yeh H; Smoot E; Schoenfeld DA; Markmann JF
    Transplantation; 2011 Feb; 91(4):479-86. PubMed ID: 21200366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of MELD on OPTN liver allocation: preliminary results.
    Edwards EB; Harper AM
    Clin Transpl; 2002; ():21-8. PubMed ID: 12971434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes.
    Trotter JF; Osgood MJ
    JAMA; 2004 Apr; 291(15):1871-4. PubMed ID: 15100206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival on waiting list for liver transplantation before and after introduction of the model for end-stage liver disease score.
    Tenório AL; Macedo FI; Miranda LE; Fernandes JL; da Silva CM; Neto OL; Lacerda CM
    Transplant Proc; 2010 Mar; 42(2):407-11. PubMed ID: 20304152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geographic Disparity in Deceased Donor Liver Transplant Rates Following Share 35.
    Bowring MG; Zhou S; Chow EKH; Massie AB; Segev DL; Gentry SE
    Transplantation; 2019 Oct; 103(10):2113-2120. PubMed ID: 30801545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Liver Allocation Using Optimized Neighborhoods.
    Kilambi V; Mehrotra S
    Transplantation; 2017 Feb; 101(2):350-359. PubMed ID: 27906775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in access to liver transplantation: disease severity, waiting time, and transplantation center volume.
    Ahmad J; Bryce CL; Cacciarelli T; Roberts MS
    Ann Intern Med; 2007 May; 146(10):707-13. PubMed ID: 17502631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-weighting the model for end-stage liver disease score components.
    Sharma P; Schaubel DE; Sima CS; Merion RM; Lok AS
    Gastroenterology; 2008 Nov; 135(5):1575-81. PubMed ID: 18835388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraregional model for end-stage liver disease score variation in liver transplantation: Disparity in our own backyard.
    Croome KP; Lee DD; Burns JM; Keaveny AP; Taner CB
    Liver Transpl; 2018 Apr; 24(4):488-496. PubMed ID: 29365357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex-based disparities in liver transplant rates in the United States.
    Mathur AK; Schaubel DE; Gong Q; Guidinger MK; Merion RM
    Am J Transplant; 2011 Jul; 11(7):1435-43. PubMed ID: 21718440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparities in liver transplantation before and after introduction of the MELD score.
    Moylan CA; Brady CW; Johnson JL; Smith AD; Tuttle-Newhall JE; Muir AJ
    JAMA; 2008 Nov; 300(20):2371-8. PubMed ID: 19033587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABO blood group-related waiting list disparities in liver transplant candidates: effect of the MELD adoption.
    Barone M; Avolio AW; Di Leo A; Burra P; Francavilla A
    Transplantation; 2008 Mar; 85(6):844-9. PubMed ID: 18360266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease.
    Nadim MK; DiNorcia J; Ji L; Groshen S; Levitsky J; Sung RS; Kim WR; Andreoni K; Mulligan D; Genyk YS
    J Hepatol; 2017 Sep; 67(3):517-525. PubMed ID: 28483678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the model of end-stage liver disease (MELD) valid in Israel? A critical analysis of liver transplant waiting list mortality.
    Ben-Haim M; Carmiel M; Katz P; Shabtai E; Oren R; Nakache R
    Isr Med Assoc J; 2006 Sep; 8(9):605-9. PubMed ID: 17058408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates.
    Sharma P; Schaubel DE; Gong Q; Guidinger M; Merion RM
    Hepatology; 2012 Jan; 55(1):192-8. PubMed ID: 21898487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waiting list removal rates among patients with chronic and malignant liver diseases.
    Freeman RB; Edwards EB; Harper AM
    Am J Transplant; 2006 Jun; 6(6):1416-21. PubMed ID: 16686765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation.
    Volk ML; Lok AS; Pelletier SJ; Ubel PA; Hayward RA
    Gastroenterology; 2008 Nov; 135(5):1568-74. PubMed ID: 19009713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of broader regional sharing of livers: 2-year results of "Share 35".
    Edwards EB; Harper AM; Hirose R; Mulligan DC
    Liver Transpl; 2016 Apr; 22(4):399-409. PubMed ID: 26890858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage of cirrhosis predicts the risk of liver-related death in patients with low Model for End-Stage Liver Disease scores and cirrhosis awaiting liver transplantation.
    Wedd J; Bambha KM; Stotts M; Laskey H; Colmenero J; Gralla J; Biggins SW
    Liver Transpl; 2014 Oct; 20(10):1193-201. PubMed ID: 24916539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.